US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Actuate Therapeutics Inc

8.61

-0.0600-0.69%

Post-market: 8.610.00000.00%16:04 EDT

Volume:59.53K

Turnover:514.35K

Market Cap:168.93M

PE:-4.38

High:9.25

Open:8.54

Low:8.24

Close:8.67

Loading ...

Overview Company News Filings

Actuate Therapeutics Hosts Key Opinion Leader Event

Actuate Therapeutics Unveils Phase 2 Topline Data for Elraglusib in Pancreatic Cancer at Key Opinion Leader Event

Actuate Therapeutics shares highlights from KOL eventon elraglusib data

Actuate Therapeutics' Shares Gain on Positive Phase 2 Trial for Pancreatic Cancer Treatment

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at Asco 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

THOMSON REUTERS

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

The 10 occupations targeted by ACTU gender pay blitz

The Australian Financial Review

Actuate Therapeutics Elects Directors at Annual Meeting

Actuate Therapeutics Inc. Held Virtual Annual Stockholders Meeting

Actuate Therapeutics Announces Details for 2025 Asco Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Marriott, IQVIA

BUZZ-Actuate rises as pancreatic cancer drug succeeds in mid-stage trial

Actuate Therapeutics Announces Statistically Significant Topline Results From Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

THOMSON REUTERS

Actuate Therapeutics Inc: Plans to Work With Regulators to Expeditiously Bring Elraglusib to Commercialization

THOMSON REUTERS

Actuate Therapeutics Inc: Clinical Trial Meets Primary Endpoint for Overall Survival and Confirms Significant 1-Year Survival Rate

THOMSON REUTERS

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

ACTU pushes for 4.5 per cent lift in minimum wage at Fair Work Commission

Sydney Morning Herald

BRIEF-Actuate Therapeutics Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACTU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACTU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","market":"US","secType":"STK","nameCN":"Actuate Therapeutics Inc","latestPrice":8.61,"timestamp":1749758400000,"preClose":8.67,"halted":0,"volume":59526,"hourTrading":{"tag":"盘后","latestPrice":8.61,"preClose":8.61,"latestTime":"16:04 EDT","volume":169,"amount":1455.09,"timestamp":1749758658161},"delay":0,"floatShares":6049455,"shares":19619660,"eps":-1.967312,"marketStatus":"Post-Mkt","change":-0.06,"latestTime":"06-12 18:55:39 EDT","open":8.54,"high":9.2475,"low":8.24,"amount":514351.7385,"amplitude":0.116205,"askPrice":8.75,"askSize":485,"bidPrice":7.21,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.967312,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1749772800000},"marketStatusCode":4,"adr":0,"listingDate":1723521600000,"exchange":"NASDAQ","adjPreClose":8.67,"postHourTrading":{"tag":"盘后","latestPrice":8.61,"preClose":8.61,"latestTime":"16:04 EDT","volume":169,"amount":1455.09,"timestamp":1749758658161},"volumeRatio":1.743207},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","floatShares":6049455,"roa":"-413.43%","roe":"--","lyrEps":-3.258828,"volumeRatio":1.743207,"shares":19619660,"dividePrice":0,"high":9.2475,"amplitude":0.116205,"preClose":8.67,"low":8.24,"week52Low":5.51,"pbRate":"-33.20","week52High":11.99,"institutionHeld":0,"latestPrice":8.61,"committee":-0.65812,"eps":-1.967312,"divideRate":0,"volume":59526,"delay":0,"ttmEps":-1.967312,"open":8.54,"prevYearClose":7.96,"prevWeekClose":8.96,"prevMonthClose":11.9,"prevQuarterClose":6.77,"fiveDayClose":9.09,"twentyDayClose":9.65,"sixtyDayClose":7.46},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACTU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541589003","title":"Actuate Therapeutics Hosts Key Opinion Leader Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2541589003","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541589003?lang=en_us&edition=fundamental","pubTime":"2025-06-06 03:17","pubTimestamp":1749151057,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics, Inc. ( ($ACTU) ) just unveiled an announcement. On May 31, 2025, Actuate Therapeutics hosted a Key Opinion Leader event to di...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-hosts-key-opinion-leader-event?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-hosts-key-opinion-leader-event?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","ACTU","LENZ"],"gpt_icon":0},{"id":"2541008402","title":"Actuate Therapeutics Unveils Phase 2 Topline Data for Elraglusib in Pancreatic Cancer at Key Opinion Leader Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2541008402","media":"Reuters","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541008402?lang=en_us&edition=fundamental","pubTime":"2025-06-06 02:58","pubTimestamp":1749149923,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL23X3CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2540379306","title":"Actuate Therapeutics shares highlights from KOL eventon elraglusib data","url":"https://stock-news.laohu8.com/highlight/detail?id=2540379306","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540379306?lang=en_us&edition=fundamental","pubTime":"2025-06-02 21:15","pubTimestamp":1748870132,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced key takeaways from its Key Opinion Leader event held on May 31, 2025 discussing the topline results from the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-shares-highlights-from-kol-eventon-elraglusib-data-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-shares-highlights-from-kol-eventon-elraglusib-data-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4007","KOL","ACTU","BK4139"],"gpt_icon":0},{"id":"2540762387","title":"Actuate Therapeutics' Shares Gain on Positive Phase 2 Trial for Pancreatic Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540762387","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540762387?lang=en_us&edition=fundamental","pubTime":"2025-06-02 18:34","pubTimestamp":1748860440,"startTime":"0","endTime":"0","summary":"Shares of Actuate Therapeutics climbed after data from a recent trial of the company's in-development pancreatic cancer treatment showed that the drug improved overall survival.The stock rose 15% to $13.63, in pre-market trading Monday. Its shares, which began publicly trading last August, hit a high of $11.99 on Friday and are up 50% so far this year.The clinical-stage biopharmaceutical company said its phase 2 study of the drug, elraglusib, met its primary endpoint of improved median overall survival. Median overall survival increased by almost three months, with a 37% reduction in the risk of death and strong statistical significance.These results represent a clinically meaningful advance in the potential treatment of metastatic pancreatic ductal adenocarcinoma, an aggressive form of pancreatic cancer in which the tumor has spread to other parts of the body, the company said.\"Based on the clear clinical benefit and well-tolerated safety profile, we intend to engage with the FDA and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACTU","BK4139","LENZ","BK4539"],"gpt_icon":0},{"id":"2540782673","title":"Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at Asco 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2540782673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540782673?lang=en_us&edition=fundamental","pubTime":"2025-06-01 04:30","pubTimestamp":1748723402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nTUA9MBDLS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2540675793","title":"Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2540675793","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540675793?lang=en_us&edition=fundamental","pubTime":"2025-06-01 04:30","pubTimestamp":1748723400,"startTime":"0","endTime":"0","summary":"Phase 2  trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival  in previously untreated patients with metastatic pancreatic ductal adenocarcinoma  receiving elraglusib/GnP. Risk of death was reduced by 37%  in patients treated with elraglusib/GnP. Data featured as an oral presentation at the ASCO Annual Meeting. Company plans to engage with FDA in the second half of 2025 to align on a path towards product registration. The trial met its primary endpoint of improved median overall survival. Median overall survival  increased by almost three months  with a 37% reduction in the risk of death and strong statistical significance, representing a clinically meaningful advance in the potential treatment of mPDAC. Patients receiving elraglusib with GnP achieved a 12-month survival rate in 44.1% of patients treated—double that of GnP alone .Daniel Schmitt, President & Chief Executive Officer of Actuate added, “We significantly improved mOS, cut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actuate-therapeutics-presents-topline-elraglusib-203000713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACTU","BK4539","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2538114412","title":"The 10 occupations targeted by ACTU gender pay blitz","url":"https://stock-news.laohu8.com/highlight/detail?id=2538114412","media":"The Australian Financial Review","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538114412?lang=en_us&edition=fundamental","pubTime":"2025-05-25 16:41","pubTimestamp":1748162460,"startTime":"0","endTime":"0","summary":"Unions are lining up hundreds of thousands of workers for the next wave of gender pay increases, from retail staff and hairdressers to legal conveyancers and receptionists.The ACTU has asked the Fair Work Commission’s minimum wage panel to prioritise 10 occupations for pay reviews in its decision next month and has flagged several more in the coming years, covering about 350,000 workers.Loading...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.afr.com/work-and-careers/workplace/gender-pay-wave-to-hit-business-actu-moves-on-priority-list-20250525-p5m1z8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"afr_stock","symbols":["ACTU"],"gpt_icon":0},{"id":"2537815221","title":"Actuate Therapeutics Elects Directors at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2537815221","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537815221?lang=en_us&edition=fundamental","pubTime":"2025-05-24 04:32","pubTimestamp":1748032356,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics, Inc. ( ($ACTU) ) just unveiled an update. On May 22, 2025, Actuate Therapeutics, Inc. held its Annual Meeting of Stockholders...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-elects-directors-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-elects-directors-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","ACTU","LENZ"],"gpt_icon":0},{"id":"2537755154","title":"Actuate Therapeutics Inc. Held Virtual Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2537755154","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537755154?lang=en_us&edition=fundamental","pubTime":"2025-05-24 04:11","pubTimestamp":1748031070,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics, Inc. held its Annual Meeting of Stockholders virtually on May 22, 2025. During the meeting, stockholders elected Dr. Roger Sawhney, Mr. Todd Thomson, and Dr. Dan Zabrowski to the Board of Directors. Additionally, the appointment of Crowe LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Both proposals were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 23, 2025, and is solely responsible for the information contain","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL2HFMst:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2537736927","title":"Actuate Therapeutics Announces Details for 2025 Asco Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2537736927","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537736927?lang=en_us&edition=fundamental","pubTime":"2025-05-23 05:05","pubTimestamp":1747947900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUA9GVBNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2533640636","title":"BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Marriott, IQVIA","url":"https://stock-news.laohu8.com/highlight/detail?id=2533640636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533640636?lang=en_us&edition=fundamental","pubTime":"2025-05-06 21:04","pubTimestamp":1746536661,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Marriott, IQVIAEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nL6N3RE0CJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0048584097.USD","IQV","LU2023250330.USD","JELD","BK4563","LU2286300806.USD","BALL","AU","LMND","LU0075056555.USD","ROO.UK","ACTU","LU1119994496.HKD","LU2065171402.SGD","BK4570","SEDG","LU0310799852.SGD","IE00BBT3K403.USD","AME","NEM","KLG","LU1366192091.USD","PTLO","IE00BGHQF417.EUR","LU0330918003.SGD","CELH","FSUN","CEG","LU1791710400.SGD","DDOG","CHD","ETN","LU0345780281.USD","VRTX","F","BK4567","LU1496350171.SGD","MAR","FARO","BK4018","LU1861220207.SGD","GPN","LU0868494708.USD","BR","CMI","LU2505996509.AUD","MRSN","SG9999001176.SGD","DASH"],"gpt_icon":1},{"id":"2533635558","title":"BUZZ-Actuate rises as pancreatic cancer drug succeeds in mid-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2533635558","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533635558?lang=en_us&edition=fundamental","pubTime":"2025-05-06 20:47","pubTimestamp":1746535675,"startTime":"0","endTime":"0","summary":"BUZZ-Actuate rises as pancreatic cancer drug succeeds in mid-stage trial** Shares of drug developer Actuate Therapeutics ACTU.O rise 7.2% to $10.6 premarket ** ACTU's experimental drug, elraglusib, in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nL6N3RE0H1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2533687405","title":"Actuate Therapeutics Announces Statistically Significant Topline Results From Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2533687405","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533687405?lang=en_us&edition=fundamental","pubTime":"2025-05-06 20:02","pubTimestamp":1746532978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE1UZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2533687268","title":"Actuate Therapeutics Inc: Plans to Work With Regulators to Expeditiously Bring Elraglusib to Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2533687268","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533687268?lang=en_us&edition=fundamental","pubTime":"2025-05-06 20:02","pubTimestamp":1746532978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE1UZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2533687252","title":"Actuate Therapeutics Inc: Clinical Trial Meets Primary Endpoint for Overall Survival and Confirms Significant 1-Year Survival Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533687252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533687252?lang=en_us&edition=fundamental","pubTime":"2025-05-06 20:02","pubTimestamp":1746532978,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE1UZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2531031444","title":"Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031444","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031444?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:00","pubTimestamp":1746014400,"startTime":"0","endTime":"0","summary":"CHICAGO and FORT WORTH, Texas, April 30, 2025  -- Actuate Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta , today announced that Daniel Schmitt, President & Chief Executive Officer of Actuate will present at the Citizens Life Sciences Conference 2025 taking place May 7-8 in New York, NY.The webcast of the presentation will be accessible in the Investor section of the Actuate website.The Actuate management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with management should contact their Citizens JMP representative.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actuate-therapeutics-participate-citizens-life-120000302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ACTU","BK4007","LENZ"],"gpt_icon":0},{"id":"2529363399","title":"Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529363399","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529363399?lang=en_us&edition=fundamental","pubTime":"2025-04-23 22:24","pubTimestamp":1745418240,"startTime":"0","endTime":"0","summary":"- Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel  in first-line treatment of metastatic pancreatic ductal adenocarcinoma . CHICAGO and FORT WORTH, Texas, April 23, 2025  -- Actuate Therapeutics, Inc.  , a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta , today announced that topline clinical data from the randomized Phase 2 study  evaluating elraglusib have been selected for oral presentation at the 2025 American Society of Clinical Oncology  Annual Meeting, to take place May 30- June 3, in Chicago, Illinois.Abstract Title: Preliminary results from the randomized phase 2 study  of elraglusib in combination with gemcitabine/nab-paclitaxel  versus GnP alone in patients  with previously untreated metastatic pancreatic ductal adenocarcinoma .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actuate-present-elraglusib-phase-2-142400619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACTU","BK4139","AFG","BK4107","BK4117"],"gpt_icon":0},{"id":"2528190277","title":"Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2528190277","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528190277?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:00","pubTimestamp":1744891200,"startTime":"0","endTime":"0","summary":"CHICAGO and FORT WORTH, Texas, April 17, 2025  -- Actuate Therapeutics, Inc.  , a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta , today announced that data on elraglusib in advanced salivary gland carcinoma will be presented in a poster session at the American Association for Cancer Research  Annual Meeting 2025 taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. The abstracts will be published in the online Proceedings of the AACR.Poster presentation details:Title: Elraglusib, a glycogen synthase kinase 3 beta  inhibitor, plus chemotherapy with or without immunotherapy for advanced salivary gland cancerSession Title: Phase II Clinical Trials 2Session Date and Time: April 29, 2025, 2:00 PM - 5:00 PMLocation: Poster Section 50Abstract Presentation Number: CT212","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actuate-present-promising-data-elraglusib-120000563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACTU","IE00B7SZL793.SGD","AEIS","IE00B19Z4B17.USD","IE0031619046.USD","BK4157","IE00B66KJ199.SGD","BK4139"],"gpt_icon":0},{"id":"2524421463","title":"ACTU pushes for 4.5 per cent lift in minimum wage at Fair Work Commission","url":"https://stock-news.laohu8.com/highlight/detail?id=2524421463","media":"Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524421463?lang=en_us&edition=fundamental","pubTime":"2025-04-03 08:38","pubTimestamp":1743640723,"startTime":"0","endTime":"0","summary":"Union leader Sally McManus has fronted the Fair Work Commission to push for a big minimum wage increase for workers.","market":"nz","thumbnail":"https://images.perthnow.com.au/publication/C-18250086/007f86a8bae46d76ad8291e42c44f792cef6d921-16x9-x0y192w2048h1152.jpg","type":0,"news_type":0,"thumbnails":["https://images.perthnow.com.au/publication/C-18250086/007f86a8bae46d76ad8291e42c44f792cef6d921-16x9-x0y192w2048h1152.jpg"],"rights":{"source":"perthnow_stock","url":"https://www.perthnow.com.au/business/actu-pushes-for-45-per-cent-lift-in-minimum-wage-at-fair-work-commission-c-18250086","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.perthnow.com.au/business/actu-pushes-for-45-per-cent-lift-in-minimum-wage-at-fair-work-commission-c-18250086","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"perthnow_stock","symbols":["XAO.AU","BK4139","XKO.AU","ACTU","XJO.AU"],"gpt_icon":0},{"id":"2522057953","title":"BRIEF-Actuate Therapeutics Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc","url":"https://stock-news.laohu8.com/highlight/detail?id=2522057953","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522057953?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:40","pubTimestamp":1743165619,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc March 28  - Actuate Therapeutics Inc ACTU.O:ACTUATE THERAPEUTICS INC - ENTERS STOCK PURCHASE AGREEMENT WITH B. RILEY PRINCIPAL CAPITAL II, LLC - SEC FILINGACTUATE THERAPEUTICS INC - HAVE THE RIGHT TO SELL UP TO $50 MILLION  NEWLY ISSUED SHARES  - SEC FILINGFurther company coverage: ACTU.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB02A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":52,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACTU\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"ACTU","fiscalQuarterEnding":"2025/03","expectedEps":-0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACTU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACTU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1745380800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACTU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACTU","date":"2025-06-11","current":-6.667475,"percent":0.140845,"low":-9.225925,"twenty":-6.365148,"median":-5.691218,"eighty":-5.076133,"high":-3.930949,"avg":-5.835595,"sd":0.896162,"marketCap":168729076},"quantilePoints":[{"date":"2024-07-25","current":-6.211408,"twenty":-6.211408,"median":-6.211408,"eighty":-6.211408,"marketCap":172493433},{"date":"2024-08-09","current":-5.505609,"twenty":-6.211408,"median":-6.211408,"eighty":-6.070248,"marketCap":152893088},{"date":"2024-08-16","current":-5.987349,"twenty":-6.211408,"median":-6.167236,"eighty":-5.841451,"marketCap":166271233},{"date":"2024-08-23","current":-5.560665,"twenty":-6.211408,"median":-5.987349,"eighty":-5.556536,"marketCap":154422018},{"date":"2024-08-30","current":-5.540019,"twenty":-6.211408,"median":-5.870355,"eighty":-5.533137,"marketCap":153848669},{"date":"2024-09-06","current":-5.608839,"twenty":-6.158401,"median":-5.624324,"eighty":-5.529008,"marketCap":155759833},{"date":"2024-09-13","current":-5.512491,"twenty":-6.078798,"median":-5.608839,"eighty":-5.512491,"marketCap":153084204},{"date":"2024-09-20","current":-5.03075,"twenty":-6.012125,"median":-5.608839,"eighty":-5.509738,"marketCap":139706059},{"date":"2024-09-27","current":-4.249491,"twenty":-5.950186,"median":-5.560665,"eighty":-5.486339,"marketCap":122463357},{"date":"2024-10-04","current":-5.056014,"twenty":-5.921282,"median":-5.540019,"eighty":-5.041842,"marketCap":145706004},{"date":"2024-10-11","current":-4.981461,"twenty":-5.86072,"median":-5.519373,"eighty":-4.824223,"marketCap":143557524},{"date":"2024-10-18","current":-4.920464,"twenty":-5.785018,"median":-5.512491,"eighty":-4.844556,"marketCap":141799677},{"date":"2024-10-25","current":-5.774428,"twenty":-5.765917,"median":-5.512491,"eighty":-4.844556,"marketCap":166409538},{"date":"2024-11-01","current":-5.306781,"twenty":-5.809795,"median":-5.512491,"eighty":-4.893354,"marketCap":152932709},{"date":"2024-11-08","current":-5.937088,"twenty":-5.927371,"median":-5.540019,"eighty":-4.957062,"marketCap":171097131},{"date":"2024-11-15","current":-5.958745,"twenty":-5.939799,"median":-5.550342,"eighty":-5.011034,"marketCap":169534600},{"date":"2024-11-22","current":-6.164693,"twenty":-5.973458,"median":-5.595075,"eighty":-5.037775,"marketCap":175394091},{"date":"2024-11-29","current":-5.581175,"twenty":-6.024512,"median":-5.608839,"eighty":-5.04517,"marketCap":158792200},{"date":"2024-12-06","current":-6.144098,"twenty":-6.055165,"median":-5.638088,"eighty":-5.051947,"marketCap":174808142},{"date":"2024-12-13","current":-5.917556,"twenty":-6.037784,"median":-5.643249,"eighty":-5.107523,"marketCap":168362702},{"date":"2024-12-20","current":-4.647547,"twenty":-6.017783,"median":-5.638088,"eighty":-5.04517,"marketCap":132229175},{"date":"2024-12-27","current":-6.068584,"twenty":-6.019156,"median":-5.638088,"eighty":-5.043814,"marketCap":172659662},{"date":"2025-01-03","current":-5.718473,"twenty":-6.013664,"median":-5.622603,"eighty":-5.049236,"marketCap":162698527},{"date":"2025-01-10","current":-5.697878,"twenty":-5.992612,"median":-5.622603,"eighty":-5.054658,"marketCap":162112578},{"date":"2025-01-17","current":-5.917556,"twenty":-5.969958,"median":-5.636367,"eighty":-5.146627,"marketCap":168362702},{"date":"2025-01-24","current":-6.940428,"twenty":-6.032033,"median":-5.643249,"eighty":-5.178584,"marketCap":197464839},{"date":"2025-01-31","current":-6.199017,"twenty":-6.064465,"median":-5.677284,"eighty":-5.209185,"marketCap":176370673},{"date":"2025-02-07","current":-6.047989,"twenty":-6.091559,"median":-5.691423,"eighty":-5.241176,"marketCap":172073713},{"date":"2025-02-14","current":-5.327173,"twenty":-6.072917,"median":-5.687582,"eighty":-5.255778,"marketCap":151565495},{"date":"2025-02-21","current":-5.279119,"twenty":-6.065838,"median":-5.658037,"eighty":-5.254405,"marketCap":150198280},{"date":"2025-02-28","current":-4.970198,"twenty":-6.060665,"median":-5.639808,"eighty":-5.174772,"marketCap":141409044},{"date":"2025-03-07","current":-4.771115,"twenty":-6.057666,"median":-5.608839,"eighty":-5.040292,"marketCap":135744870},{"date":"2025-03-14","current":-5.189762,"twenty":-6.053039,"median":-5.581175,"eighty":-5.033989,"marketCap":141604361},{"date":"2025-03-21","current":-4.831847,"twenty":-6.048768,"median":-5.560665,"eighty":-5.014488,"marketCap":131838543},{"date":"2025-03-28","current":-5.655051,"twenty":-6.042497,"median":-5.560665,"eighty":-5.033989,"marketCap":154299924},{"date":"2025-04-04","current":-4.932064,"twenty":-6.028767,"median":-5.540019,"eighty":-4.987939,"marketCap":134572972},{"date":"2025-04-11","current":-5.483252,"twenty":-6.017783,"median":-5.519391,"eighty":-4.984609,"marketCap":149612331},{"date":"2025-04-17","current":-5.726634,"twenty":-6.012291,"median":-5.540019,"eighty":-4.990995,"marketCap":156253088},{"date":"2025-04-25","current":-6.406672,"twenty":-6.045243,"median":-5.553757,"eighty":-4.998855,"marketCap":174808142},{"date":"2025-05-02","current":-7.537682,"twenty":-6.061192,"median":-5.567445,"eighty":-5.009067,"marketCap":205668127},{"date":"2025-05-09","current":-7.408833,"twenty":-6.107591,"median":-5.601957,"eighty":-5.032369,"marketCap":202152432},{"date":"2025-05-16","current":-8.179286,"twenty":-6.139979,"median":-5.636367,"eighty":-5.039569,"marketCap":206987413},{"date":"2025-05-23","current":-7.830407,"twenty":-6.178422,"median":-5.644452,"eighty":-5.043814,"marketCap":198158566},{"date":"2025-05-30","current":-8.194792,"twenty":-6.211408,"median":-5.662735,"eighty":-5.049236,"marketCap":207379806},{"date":"2025-06-06","current":-7.047366,"twenty":-6.281396,"median":-5.690843,"eighty":-5.056014,"marketCap":178342709},{"date":"2025-06-11","current":-6.667475,"twenty":-6.365148,"median":-5.691218,"eighty":-5.076133,"marketCap":168729076}],"updateTime":1749764338074}}}